Featured Speaker: Will Singleterry, PhD, Director of Business Development, IsoPlexis
Your data is secure. We keep your personal information safe and do not share it with any third parties. By submitting this form, you agree to receive communications from Bruker Cellular Analysis and accept our Privacy Policy. You may unsubscribe at any time.
In this Webinar we discuss:
Evaluate T cell responses induced by various bispecific T cell engagers across phenotypes
Understand the heterogeneity of TIL polyfunctionality in solid tumors in response to checkpoint inhibitors
Uniquely correlate clinical anti-tumor responses with IsoPlexis data
Optimize combination cancer vaccines in melanoma using model systems
